title: Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
abstract: 46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks. Histology was confirmed by a pathology panel. None of the patients had received previous chemotherapy. Toxicity was mainly mild gastrointestinal and haematological side-effects. Out of 34 patients evaluated for response, only 1 partial response was recorded. Mitoxantrone at this dose and schedule has marginal activity in malignant mesothelioma.
authors.affiliation: Spaarne Ziekenhuis, Haarlem, The Netherlands.
authors.forename: F J
authors.initials: FJ
authors.lastname: van Breukelen
authors.forename: K
authors.initials: K
authors.lastname: Mattson
authors.forename: G
authors.initials: G
authors.lastname: Giaccone
authors.forename: N
authors.initials: N
authors.lastname: van Zandwijk
authors.forename: H T
authors.initials: HT
authors.lastname: Planteydt
authors.forename: A
authors.initials: A
authors.lastname: Kirkpatrick
authors.forename: O
authors.initials: O
authors.lastname: Dalesio
mesh_terms: D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D010997:Pleural Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D008942:Mitoxantrone